What CONTRAFECT Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Messinger Michael | Chief Financial Officer | Dec 13 | Open-market buy · P | +5,000 | $0.37 | +$1.85K | 19,091 |
| Low David N. | Director | Dec 13 | Open-market buy · P | +300,000 | $0.43 | +$129K | 370,550 |
| Sucoff Cary | Director | Dec 13 | Open-market buy · P | +50,000 | $0.39 | +$19.5K | 62,000 |
| Fosun Industrial Co., Ltd | 10% owner | Dec 04 | Open-market sale · S | −600,000 | $2.04 | −$1.22M | 7,900,000 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% owner | Dec 04 | Open-market sale · S | −600,000 | $2.04 | −$1.22M | 7,900,000 |
| Muntner Joshua B | SVP Business Development | Jul 25 | Open-market buy · P | +2,000 | $1.24 | +$2.48K | 2,000 |
| Barer Sol J | Director | Jul 25 | Open-market buy · P | +40,000 | $1.24 | +$49.6K | 815,933 |
| Pomerantz Roger | Director | Jul 25 | Open-market buy · P | +800 | $1.24 | +$992 | 800 |
| Ricciardi Lisa | Director | Jul 25 | Open-market buy · P | +9,600 | $1.24 | +$11.9K | 9,600 |
| Messinger Michael | SVP Finance | Jul 25 | Open-market buy · P | +800 | $1.24 | +$992 | 14,091 |
| Gilman Steven C | CEO | Jul 25 | Open-market buy · P | +800 | $1.24 | +$992 | 20,800 |
| Otto Michael | Director | Jul 25 | Open-market buy · P | +8,000 | $1.24 | +$9.92K | 8,000 |
| Low David N. | Director | Jul 25 | Open-market buy · P | +40,000 | $1.24 | +$49.6K | 70,550 |
| Sucoff Cary | Director | Jul 25 | Open-market buy · P | +12,000 | $1.24 | +$14.9K | 12,000 |
| Bogdanos Natalie | General Counsel | Jul 25 | Open-market buy · P | +800 | $1.24 | +$992 | 800 |
| Cassino Cara M | Chief Medical Officer | Jul 25 | Open-market buy · P | +8,000 | $1.24 | +$9.92K | 8,000 |
| Blech Isaac | Director | Jul 25 | Open-market buy · P | +16,000 | $1.24 | +$19.8K | 16,000 |
| Gilman Steven C | CEO | Jul 27 | Open-market buy · P | +20,000 | $2.48 | +$49.6K | 20,000 |
| Couto Daniel | SVP Manufacturing & Facilities | Nov 17 | Disclosed 10b5-1 sale · S | −2,872 | $3.81 | −$10.9K | 0 |
| Couto Daniel | SVP Manufacturing & Facilities | Nov 03 | Disclosed 10b5-1 sale · S | −2,867 | $4.23 | −$12.1K | 2,872 |
Loading...
